VRAY - ViewRay, Inc.
| Previous Close | 7.25 |
| Open | 7.19 |
| Bid | 6.85 x 800 |
| Ask | 7.35 x 4000 |
| Day's Range | 6.99 - 7.25 |
| 52 Week Range | 4.86 - 13.21 |
| Volume | 1,171,195 |
| Avg. Volume | 1,253,954 |
| Market Cap | 677.654M |
| Beta (3Y Monthly) | 2.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.98 |
| Earnings Date | Nov 13, 2017 - Nov 17, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.67 |
- PR Newswire•22 hours ago
ViewRay Partners with Leading Canadian Distributor to Bring MRI-guided Radiation Therapy to Canada
CLEVELAND, April 18, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that the company has partnered with Minogue Medical Inc., a leading Canadian distributor of surgical devices, operating room disposables, hospital equipment, and simulators for medical education. As part of the exclusive distribution agreement, Minogue Medical will market, sell, and support ViewRay's MRIdian MRI-guided radiation therapy system throughout Canada.
- PR Newswire•2 days ago
ViewRay Partners with Largest Independent Distributor in Australia and New Zealand to Bring Benefits of MRI-Guided Radiation Therapy to the Region
CLEVELAND, April 17, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) and Device Technologies Australia Pty Ltd (Device Technologies) announced today a partnership in which Device Technologies, the largest independent distributor in Australasia, will market, sell, and support ViewRay's MRIdian MRI-guided radiation therapy system. "Device Technologies is the ideal partner to bring the benefits of the MRIdian System to one of the biggest and best healthcare markets in the world," said Jim Alecxih, Chief Commercial Officer at ViewRay. MRIdian provides continuous high-contrast imaging of soft tissue during radiation therapy treatment to help clinicians position the patient, track tumor and anatomical motion, and accurately target treatment.
- PR Newswire•7 days ago
ViewRay Announces Conference Call and Webcast of First Quarter 2019 Financial Results to be Held After Market on May 2, 2019
ViewRay will hold a conference call to discuss results on Thursday, May 2, 2019 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 8616638.
- PR Newswire•8 days ago
ViewRay Announces Publication of Retrospective Study on MR-guided Radiation Treatment for Locally Advanced Pancreatic Cancer
CLEVELAND, April 11, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today the publication of a retrospective analysis of outcomes for the stereotactic treatment of locally advanced pancreatic cancer using precise, high-dose MRI-guided radiation therapy delivered with MRIdian's on-table adaptive dose planning system. The study, published in Cancer Medicine, and led by Soumon Rudra, M.D. from Washington University in St. Louis, demonstrated enhanced overall survival while resulting in lower levels of toxicity compared to lower-dose, mostly non-adaptive treatment.
- Zacks•14 days ago
ViewRay (VRAY) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, ViewRay (VRAY) closed at $7.72, marking a -0.13% move from the previous day.
- Zacks•27 days ago
ViewRay (VRAY) Stock Moves -1.59%: What You Should Know
In the latest trading session, ViewRay (VRAY) closed at $8.37, marking a -1.59% move from the previous day.
- Thomson Reuters StreetEvents•last month
Edited Transcript of VRAY earnings conference call or presentation 14-Mar-19 8:30pm GMT
Q4 2018 ViewRay Inc Earnings Call
- Simply Wall St.•last month
How Do Analysts See ViewRay, Inc. (NASDAQ:VRAY) Performing In The Next Couple Of Years?
ViewRay, Inc.'s (NASDAQ:VRAY) most recent earnings announcement in December 2018 indicated company earnings became less negative compared to the previous year's level - great news for investors Investors may findRead More...
- Zacks•last month
Fluidigm (FLDM) in Focus: Stock Moves 8% Higher
Fluidigm (FLDM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Motley Fool•last monthViewRay, Inc. (VRAY) Q4 2018 Earnings Conference Call Transcript
VRAY earnings call for the period ending December 31, 2018.
- Associated Press•last month
ViewRay: 4Q Earnings Snapshot
The Oakwood Village, Ohio-based company said it had a loss of 17 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
- PR Newswire•last month
ViewRay Reports Fourth Quarter and Full Year 2018 Results
CLEVELAND , March 14, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the fourth quarter and full year ended December 31, 2018 . Full Year 2018 Highlights: Total ...
- ACCESSWIRE•last month
ViewRay, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / ViewRay, Inc. (NASDAQ: VRAY ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 14, 2019, 2018 at 4:30 PM ...
- PR Newswire•2 months ago
ViewRay Announces FDA 510(k) Clearance for Advancements in MRI and Functional Imaging Technologies for MRIdian MRI-Guided Radiation Therapy System
Proprietary Technology from ViewRay Enables Imaging and Treatment Enhancements CLEVELAND , Feb. 21, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), announced today that the company received 510(k) clearance ...
- GlobeNewswire•2 months ago
New Research Coverage Highlights GoPro, McCormick & Company, CenterPoint Energy, ViewRay, Hudson Pacific Properties, and Sterling Construction — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•2 months ago
ViewRay Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results to be Held After Market on March 14, 2019
CLEVELAND , Feb. 14, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2018 financial results. ViewRay will hold a conference ...
- PR Newswire•3 months ago
World's First MRIdian Center Celebrates Five Years of MRI-Guided Radiation Treatments
As one of the world's leading cancer centers, Siteman is known for pioneering the advancement and adoption of innovative technologies with a focus on improving patient care and outcomes. "We congratulate the Siteman team on reaching this milestone and commend them for their thought-leadership, innovation and commitment to cutting-edge cancer care," said Scott Drake, President and Chief Executive Officer of ViewRay.
- PR Newswire•3 months ago
ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 Results
CLEVELAND, Jan. 7, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The preliminary results have not been audited and are subject to change. This resulted in total fourth quarter 2018 revenue of approximately $21 million, compared to fourth quarter 2017 revenue of $19.9 million, primarily from four revenue units.
- PR Newswire•3 months ago
ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic Cancer
CLEVELAND, Jan. 4, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today the enrollment of the first patient in the Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial, a multi-center, prospective clinical trial for locally advanced or borderline pancreatic cancer. The trial will explore the clinical benefits of precise, high dose radiation therapy enabled by MR-guidance combined with daily on-table adaptation in the treatment of pancreatic cancer. Retrospective analysis of precise, high-dose MR-guided radiation therapy delivered using adaptive dose planning has shown promising results with locally advanced pancreatic cancer, suggesting the potential for improving overall survival relative to patients receiving lower radiation doses, without increasing the rate of serious gastrointestinal toxicity. The compelling nature of the retrospective data prompted the SMART trial, aimed at investigating in a controlled, prospective manner, the robustness of this outcome and tracking quality of life over a 5-year trial period.
- Simply Wall St.•4 months ago
Have Insiders Been Buying ViewRay, Inc. (NASDAQ:VRAY) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
- Insider Monkey•4 months ago
Is ViewRay, Inc. (VRAY) A Good Stock To Buy?
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
- PR Newswire•4 months ago
ViewRay® to Present at the 37th Annual J.P. Morgan Healthcare Conference
CLEVELAND , Dec. 10, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California . ...
- Motley Fool•4 months ago
Why ViewRay Stock Lost 22% in November
Investors weren't happy with the radiation therapy specialist's latest earnings results.
- GlobeNewswire•5 months ago
Report: Exploring Fundamental Drivers Behind Wayfair, TEGNA, Genpact, ViewRay, United States Steel, and Windstream — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
